journal
MENU ▼
Read by QxMD icon Read
search

Journal of Clinical Oncology

journal
https://read.qxmd.com/read/31100038/nivolumab-alone-and-with-ipilimumab-in-previously-treated-metastatic-urothelial-carcinoma-checkmate-032-nivolumab-1-mg-kg-plus-ipilimumab-3-mg-kg-expansion-cohort-results
#1
Padmanee Sharma, Arlene Siefker-Radtke, Filippo de Braud, Umberto Basso, Emiliano Calvo, Petri Bono, Michael A Morse, Paolo A Ascierto, Jose Lopez-Martin, Peter Brossart, Kristoffer Rohrberg, Begoña Mellado, Bruce S Fischer, Stephanie Meadows-Shropshire, Abdel Saci, Margaret K Callahan, Jonathan Rosenberg
PURPOSE: CheckMate 032 is an open-label, multicohort study that includes patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated with nivolumab 3 mg/kg monotherapy every 2 weeks (NIVO3), nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks (NIVO3+IPI1), or nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks (NIVO1+IPI3)...
May 17, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31100037/perceptions-of-patients-with-breast-and-colon-cancer-of-the-management-of-cancer-related-pain-fatigue-and-emotional-distress-in-community-oncology
#2
Tenbroeck G Smith, Alyssa N Troeschel, Kathleen M Castro, Neeraj K Arora, Kevin Stein, Joseph Lipscomb, Otis W Brawley, Ryan M McCabe, Steven B Clauser, Elizabeth Ward
PURPOSE: Pain, fatigue, and distress are common among patients with cancer but are often underassessed and undertreated. We examine the prevalence of pain, fatigue, and emotional distress among patients with cancer, as well as patient perceptions of the symptom care they received. PATIENTS AND METHODS: Seventeen Commission on Cancer-accredited cancer centers across the United States sampled patients with local/regional breast (82%) or colon (18%) cancer. We received 2,487 completed surveys (61% response rate)...
May 17, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31091136/development-and-validation-of-a-cytogenetic-prognostic-index-predicting-survival-in-multiple-myeloma
#3
Aurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, Cyrille Hulin, Marie-Lorraine Chretien, Bruno Royer, Mamoun Dib, Olivier Decaux, Arnaud Jaccard, Karim Belhadj, Sabine Brechignac, Jean Fontan, Laurent Voillat, Hélène Demarquette, Philippe Collet, Philippe Rodon, Claudine Sohn, François Lifermann, Frédérique Orsini-Piocelle, Valentine Richez, Mohamad Mohty, Margaret Macro, Stéphane Minvielle, Philippe Moreau, Xavier Leleu, Thierry Facon, Michel Attal, Hervé Avet-Loiseau, Jill Corre
PURPOSE: The wide heterogeneity in multiple myeloma (MM) outcome is driven mainly by cytogenetic abnormalities. The current definition of high-risk profile is restrictive and oversimplified. To adapt MM treatment to risk, we need to better define a cytogenetic risk classification. To address this issue, we simultaneously examined the prognostic impact of del(17p); t(4;14); del(1p32); 1q21 gain; and trisomies 3, 5, and 21 in a cohort of newly diagnosed patients with MM. METHODS: Data were obtained from 1,635 patients enrolled in four trials implemented by the Intergroupe Francophone du Myélome...
May 15, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31084547/identification-and-management-of-immune-checkpoint-inhibitor-related-myocarditis-use-troponin-wisely
#4
Paolo Spallarossa, Giacomo Tini, Matteo Sarocchi, Eleonora Arboscello, Francesco Grossi, Paola Queirolo, Gabriele Zoppoli, Pietro Ameri
No abstract text is available yet for this article.
May 14, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31084546/more-is-not-always-better-the-perils-of-treatment-intensification-in-pediatric-acute-lymphoblastic-leukemia
#5
Stephen P Hunger
No abstract text is available yet for this article.
May 14, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31084545/importance-of-assessing-patient-reported-outcomes-with-salvage-autologous-transplantation-in-relapsed-multiple-myeloma
#6
Bronwen E Shaw, Anita D'Souza, Stephanie J Lee
No abstract text is available yet for this article.
May 14, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31084544/cytoreductive-surgery-with-or-without-hyperthermic-intraperitoneal-chemotherapy-for-gastric-cancer-with-peritoneal-metastases-cyto-chip-study-a-propensity-score-analysis
#7
Pierre-Emmanuel Bonnot, Guillaume Piessen, Vahan Kepenekian, Evelyne Decullier, Marc Pocard, Bernard Meunier, Jean-Marc Bereder, Karine Abboud, Frédéric Marchal, François Quenet, Diane Goere, Simon Msika, Catherine Arvieux, Nicolas Pirro, Romuald Wernert, Patrick Rat, Johan Gagnière, Jeremie H Lefevre, Thomas Courvoisier, Reza Kianmanesh, Delphine Vaudoyer, Michel Rivoire, Pierre Meeus, Guillaume Passot, Olivier Glehen
PURPOSE: Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive surgery (CRS) yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. Here we aimed to compare outcomes between CRS-HIPEC versus CRS alone (CRSa) among patients with PMs from GC. PATIENTS AND METHODS: From prospective databases, we identified 277 patients with PMs from GC who were treated with complete CRS with curative intent (no residual nodules > 2...
May 14, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31084543/pharmacologic-treatments-for-chronic-cancer-related-pain-does-anything-work
#8
Ellen M Lavoie Smith
No abstract text is available yet for this article.
May 14, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31082270/will-a-low-dose-option-improve-uptake-of-tamoxifen-for-breast-cancer-risk-reduction
#9
Carol J Fabian
No abstract text is available yet for this article.
May 13, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31082269/nab-paclitaxel-improves-disease-free-survival-in-early-breast-cancer-gbg-69-geparsepto
#10
Michael Untch, Christian Jackisch, Andreas Schneeweiss, Sabine Schmatloch, Bahriye Aktas, Carsten Denkert, Christian Schem, Hermann Wiebringhaus, Sherko Kümmel, Mathias Warm, Peter A Fasching, Marianne Just, Claus Hanusch, John Hackmann, Jens-Uwe Blohmer, Kerstin Rhiem, Wolfgang D Schmitt, Jenny Furlanetto, Bernd Gerber, Jens Huober, Valentina Nekljudova, Gunter von Minckwitz, Sibylle Loibl
PURPOSE: The GeparSepto trial demonstrated that weekly nanoparticle albumin-bound (NAB)-paclitaxel significantly improves the pathologic complete remission rate compared with weekly solvent-based (sb) paclitaxel followed by epirubicin plus cyclophosphamide as neoadjuvant treatment in patients with primary breast cancer (BC). Here, we report data on long-term outcomes. METHODS: Patients with histologically confirmed primary BC were randomly assigned in a 1:1 ratio to 12 times weekly NAB-paclitaxel 150 mg/m2 (after study amendment, 125 mg/m2 ) or weekly sb-paclitaxel 80 mg/m2 followed in both arms by four times epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks...
May 13, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31075046/subsequent-breast-cancer-in-female-childhood-cancer-survivors-in-the-st-jude-lifetime-cohort-study-sjlife
#11
Matthew J Ehrhardt, Carrie R Howell, Karen Hale, Malek J Baassiri, Carol Rodriguez, Carmen L Wilson, Surekha S Joshi, Thomas C Lemond, Sheila Shope, Rebecca M Howell, Zhaoming Wang, Deokumar Srivastava, Daniel A Mulrooney, Jinghui Zhang, Leslie L Robison, Kirsten K Ness, Melissa M Hudson
PURPOSE: Anthracycline-associated risk for subsequent breast cancer in childhood cancer survivors is hypothesized to be mediated by TP53 mutation-related gene-environment interactions. We characterized treatment/genetic risks and the impact of screening for breast cancer in the St Jude Lifetime Cohort. PATIENTS AND METHODS: Female participants underwent risk-based assessments, prior health event validation, chest radiation dosimetry, and whole genome sequencing...
May 10, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31067138/local-consolidative-therapy-vs-maintenance-therapy-or-observation-for-patients-with-oligometastatic-non-small-cell-lung-cancer-long-term-results-of-a-multi-institutional-phase-ii-randomized-study
#12
Daniel R Gomez, Chad Tang, Jianjun Zhang, George R Blumenschein, Mike Hernandez, J Jack Lee, Rong Ye, David A Palma, Alexander V Louie, D Ross Camidge, Robert C Doebele, Ferdinandos Skoulidis, Laurie E Gaspar, James W Welsh, Don L Gibbons, Jose A Karam, Brian D Kavanagh, Anne S Tsao, Boris Sepesi, Stephen G Swisher, John V Heymach
PURPOSE: Our previously published findings reported that local consolidative therapy (LCT) with radiotherapy or surgery improved progression-free survival (PFS) and delayed new disease in patients with oligometastatic non-small-cell lung cancer (NSCLC) that did not progress after front-line systemic therapy. Herein, we present the longer-term overall survival (OS) results accompanied by additional secondary end points. PATIENTS AND METHODS: This multicenter, randomized, phase II trial enrolled patients with stage IV NSCLC, three or fewer metastases, and no progression at 3 or more months after front-line systemic therapy...
May 8, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31059311/early-detection-of-metastatic-relapse-and-monitoring-of-therapeutic-efficacy-by-ultra-deep-sequencing-of-plasma-cell-free-dna-in-patients-with-urothelial-bladder-carcinoma
#13
Emil Christensen, Karin Birkenkamp-Demtröder, Himanshu Sethi, Svetlana Shchegrova, Raheleh Salari, Iver Nordentoft, Hsin-Ta Wu, Michael Knudsen, Philippe Lamy, Sia Viborg Lindskrog, Ann Taber, Mustafa Balcioglu, Søren Vang, Zoe Assaf, Shruti Sharma, Antony S Tin, Ramya Srinivasan, Dina Hafez, Thomas Reinert, Samantha Navarro, Alexander Olson, Rosalyn Ram, Scott Dashner, Matthew Rabinowitz, Paul Billings, Styrmir Sigurjonsson, Claus Lindbjerg Andersen, Ryan Swenerton, Alexey Aleshin, Bernhard Zimmermann, Mads Agerbæk, Cheng-Ho Jimmy Lin, Jørgen Bjerggaard Jensen, Lars Dyrskjøt
PURPOSE: Novel sensitive methods for early detection of relapse and for monitoring therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome for patients with bladder cancer. We addressed the prognostic and predictive impact of ultra-deep sequencing of cell-free DNA in patients before and after cystectomy and during chemotherapy. PATIENTS AND METHODS: We included 68 patients with localized advanced bladder cancer. Patient-specific somatic mutations, identified by whole-exome sequencing, were used to assess circulating tumor DNA (ctDNA) by ultra-deep sequencing (median, 105,000×) of plasma DNA...
May 6, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31050911/moving-from-poly-adp-ribose-polymerase-inhibition-to-targeting-dna-repair-and-dna-damage-response-in-cancer-therapy
#14
Charlie Gourley, Judith Balmaña, Jonathan A Ledermann, Violeta Serra, Rebecca Dent, Sibylle Loibl, Eric Pujade-Lauraine, Simon J Boulton
The DNA damage response (DDR) pathway coordinates the identification, signaling, and repair of DNA damage caused by endogenous or exogenous factors and regulates cell-cycle progression with DNA repair to minimize DNA damage being permanently passed through cell division. Severe DNA damage that cannot be repaired may trigger apoptosis; as such, the DDR pathway is of crucial importance as a cancer target. Poly (ADP-ribose) polymerase (PARP) is the best-known element of the DDR, and several PARP inhibitors have been licensed...
May 3, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31050910/reply-to-c-j-sweeney-et-al
#15
Ravi B Parikh, Vinay Prasad
No abstract text is available yet for this article.
May 3, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31050909/what-does-metastasis-free-survival-actually-mean
#16
Christopher J Sweeney, Richard De Abreu Lourenco, Anis A Hamid, Marc Buyse
No abstract text is available yet for this article.
May 3, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31050908/improving-cancer-diagnosis-and-care-patient-access-to-oncologic-imaging-expertise
#17
Sharyl J Nass, Christopher R Cogle, James A Brink, Curtis P Langlotz, Erin P Balogh, Ada Muellner, Dana Siegal, Richard L Schilsky, Hedvig Hricak
No abstract text is available yet for this article.
May 3, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31046553/oxaliplatin-plus-cetuximab-are-uncertainties-unequivocally-settled
#18
Christian Kersten, Marte Grønlie Cameron
No abstract text is available yet for this article.
May 2, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31046552/reply-to-c-kersten-et-al-and-d-a-parikh-et-al
#19
Shukui Qin, Tianshu Liu, Jin Li
No abstract text is available yet for this article.
May 2, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31046551/cognitive-implications-of-ototoxicity-in-pediatric-patients-with-embryonal-brain-tumors
#20
Traci W Olivier, Johnnie K Bass, Jason M Ashford, Rebecca Beaulieu, Sarah M Scott, Jane E Schreiber, Shawna Palmer, Donald J Mabbott, Michelle A Swain, Melanie Bonner, Robyn Boyle, Mary Lynn Chapeiski, Karen D Evankovich, Carol L Armstrong, Sarah J Knight, Shengjie Wu, Arzu Onar-Thomas, Amar Gajjar, Heather M Conklin
PURPOSE: Sensorineural hearing loss (SNHL) is associated with intellectual and academic declines in children treated for embryonal brain tumors. This study expands upon existing research by examining core neurocognitive processes that may result in reading difficulties in children with treatment-related ototoxicity. PATIENTS AND METHODS: Prospectively gathered, serial, neuropsychological and audiology data for 260 children and young adults age 3 to 21 years (mean, 9...
May 2, 2019: Journal of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"